Table 4.
Subgroup analysis for the prevalence of venous thromboembolism in ovarian cancer patients receiving chemotherapy
| Subgroups | No. of studies | Pooled rate with 95% CI | I2 (%) |
|---|---|---|---|
| The overall pooled result | 11 | 0.09 (0.06, 0.12) | 88.9 |
| Publication time | |||
| ≤ 2009 | 3 | 0.06 (0.02, 0.09) | 89.9 |
| > 2010 | 8 | 0.10 (0.08, 0.12) | 22.8 |
| Region | |||
| Asia | 2 | 0.11 (0.07–0.15) | 40 |
| Europe | 6 | 0.08 (0.04–0.12) | 88.9 |
| The USA | 3 | 0.09 (0.06–0.13) | 38.9 |
| Disease status | |||
| Ovarian cancer | 5 | 0.10 (0.07–0.12) | 52.7 |
| Advanced ovarian cancer | 4 | 0.08 (0.02–0.14) | 85.4 |
| Recurrent ovarian cancer | 2 | 0.08 (0.03–0.13) | 15.3 |
| Operation type | |||
| Debulking surgery | 6 | 0.08 (0.04–0.12) | 85.7 |
| Radical surgery | 5 | 0.10 (0.07–0.13) | 65.7 |
| Sample size | |||
| ≤ 500 | 9 | 0.10 (0.08–0.12) | 22.2 |
| > 500 | 2 | 0.05 (0.01–0.09) | 92.6 |
| VTE diagnostic criterion | |||
| Self-definition | 8 | 0.10 (0.08–0.12) | 27.6 |
| CTC | 3 | 0.05 (0.01–0.10) | 87.5 |
| Study design | |||
| Case-control | 6 | 0.09 (0.05–0.13) | 91.9 |
| Cross-sectional study | 2 | 0.08 (0.05–0.12) | 0 |
| Retrospective cohort | 3 | 0.10 (0.06–0.14) | 55.6 |
| NOS score | |||
| ≤ 6 | 2 | 0.08 (0.05–0.12) | 0 |
| > 6 | 9 | 0.09 (0.06–0.12) | 90.4 |
CI confidence interval, CTC Common Toxicity Criteria